CRSP
CRISPR Therapeutics AG
There isn't enough reported data to score CRSP yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CRSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CRSP's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRSP PE Valuation
CRSP has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
CRSP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CRSP's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.69 | +$0.87 |
| Q2 2026 | -$4.71 | +$0.69 |
| Q1 2026 | -$6.17 | -$1.68 |
| Q4 2025 | -$6.47 | -$2.13 |
| Q3 2025 | -$5.56 | -$2.75 |
| Q2 2025 | -$5.40 | -$2.19 |
| Q1 2025 | -$4.49 | -$1.79 |
| Q4 2024 | -$4.34 | -$2.40 |
CRSP is still losing money, but less than at its worst: $4.69 per share over the past year, against $8.52 at its worst in late 2022.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CRSP on earnings quality, reporting a profit while its opponent remains loss making.
CRSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.7M | +1325% |
| Q2 2026 | $10.2M | +1041% |
| Q1 2026 | $1.5M | +69% |
| Q4 2025 | $864K | -98% |
| Q3 2025 | $889K | +48% |
| Q2 2025 | $892K | +73% |
| Q1 2025 | $865K | +72% |
| Q4 2024 | $35.7M | -82% |
CRSP's revenue is recovering but still below its 2021 peak: $13M last quarter, up 1325% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1026% | +13828 points |
| Q2 2026 | -1152% | +24557 points |
| Q1 2026 | -8933% | +8226 points |
| Q4 2025 | -17913% | -17732 points |
| Q3 2025 | -14855% | +3439 points |
| Q2 2025 | -25709% | +3548 points |
| Q1 2025 | -17159% | +10735 points |
| Q4 2024 | -181% | -216 points |
CRSP's operating margin was −1026% last quarter, up 13828 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over CRSP on profitability, with a higher operating margin.
CRSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.1M | -$5.4M |
| Q2 2026 | -$84.1M | +$29.9M |
| Q1 2026 | -$109.4M | -$55.2M |
| Q4 2025 | -$93.1M | -$42.8M |
| Q3 2025 | -$84.7M | +$22.4M |
| Q2 2025 | -$114M | -$17.7M |
| Q1 2025 | -$54.2M | -150% |
| Q4 2024 | -$50.3M | +$46.5M |
CRSP has burned cash in almost every quarter: −$377M over the past year, against −$303M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CRSP on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +227K shares |
| 1 year | +6% | +5.4M shares |
| 3 years | +22% | +17.3M shares |
| 5 years | +27% | +20.5M shares |
| Available history | +61% | +36.5M shares |
CRSP has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -2.4x | Net Cash |
| Q3 2021 | -2.4x | Net Cash |
| Q2 2021 | -3.6x | Net Cash |
| Q2 2020 | -329.4x | Net Cash |
| Q1 2020 | -32.3x | Net Cash |
| Q4 2019 | -18.3x | Net Cash |
CRSP has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
CRSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 17.4 | Oversold |
CRSP's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRSP PE vs Healthcare Sector
| Metric | CRSP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CRSP has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $50.7 | 16% below |
| 20 week MA | $52.5 | 19% below |
| 50 week MA | $52.7 | 19% below |
| 100 week MA | $50.8 | 16% below |
| 200 week MA | $53.0 | 20% below |
CRSP is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over CRSP on trend strength, trading above more of its moving averages.
CRSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $168.5 | +155% |
| 2021 | $168.5 | $82.2 | -51% |
| 2022 | $82.2 | $44.1 | -46% |
| 2023 | $44.1 | $62.6 | +42% |
| 2024 | $62.6 | $40.0 | -36% |
| 2025 | $40.0 | $55.1 | +38% |
| 2026 YTD | $55.1 | $42.6 | -23% |
CRSP's yearly returns have swung widely, from +155% in 2020 to −51% in 2021. It's down 23% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRSP on returns for 2026, with the stronger performance.